“Treat-to-target” approach is underpinned by new findings

The treatment arsenal for chronic urticaria includes several 2nd generation antihistamines – still the treatment of first choice – the monoclonal antibody Omalizumab and the immunosuppressant Ciclosporin A as an add-on. There are interesting new findings from various studies with regard to dosage regimes and prediction of treatment response. There is much to be said for an individualized approach within the framework of the scheme recommended by the guideline.